September 09, 2020
AstraZeneca has stopped giving shots of its experimental Coronavirus vaccine after a person who voluntarily participated got sick. Along with the University of Oxford, the company is forming the vaccine for the world’s deadliest virus, COVID-19. It is also among the nine companies in late-stage Phase 3 trials for their vaccine candidates.
In an official statement, this Pharmaceutical Company said that they had halted the drug’s voluntary experimentation after a volunteer developed an unexplained illness. It is a randomized clinical trial of the COVID-19 vaccine. The spokesperson informed that as a part of the continuous randomized, the standard review process was activated. The company has voluntarily paused the vaccination for evaluating the safety data by a self-governing committee. They further informed that this is a regular activity that needs to happen whenever there is a possibly unexplained illness on trial. In such large practices, some illness occurs by chance, and then it must be examined instantly. The company is carefully monitoring that patient’s health condition and soon will be figuring out the actual reason behind it. They didn’t reveal any further information about the possible side effects except to call it “a potentially unexplained illness.”
“We are working to expedite the review of the single event to minimise any potential impact on the trial timeline. It was unclear that where the patient was or the nature and severity of their illness. We are working to expedite the review of the single event to minimize any potential impact on the trial timeline,” the spokesperson added.
Holding the clinical trial is not something new in the medical field, but this is thought to be the first time for a COVID-19 vaccine trial.
Article Written by Dikhya Mohanty
Image Source: Google
Chief Minister Arvind Kejriwal on Tuesday said Covid cases are on the rise in Delhi ...
PSU major Indian Oil Corporation (IOC) will soon conduct a trial run for transporting fuel ...
Riled by Sri Lanka's request to defer the planned docking of a high-tech Chinese research ...